Nuo Therapeutics initiated with a Buy at Roth Capital

Roth Capital analyst Kyle Bauser initiated coverage of Nuo Therapeutics (AURX) with a Buy rating and $3 price target The firm sees the company’s technology as positioned for “significant growth” in the coming quarters following the favorable hospital outpatient department and physician office Medicare reimbursement along with accelerated adoption in Q3. Under its current cost structure, Nuo can reach profitability within the next 12-18 months, the analyst tells investors in a research note.